Sujay Kango - Sep 27, 2021 Form 4 Insider Report for ACCELERON PHARMA INC (XLRN)

Role
EVP, Chief Commercial Officer
Signature
/s/ Adam M. Veness, as attorney-in-fact for Sujay Kango
Stock symbol
XLRN
Transactions as of
Sep 27, 2021
Transactions value $
-$671,950
Form type
4
Date filed
9/27/2021, 07:21 PM
Previous filing
Sep 22, 2021
Next filing
Nov 22, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XLRN Common Stock Options Exercise $203K +5K +27.01% $40.61 23.5K Sep 27, 2021 Direct F1
transaction XLRN Common Stock Sale -$875K -5K -21.27% $175.00 18.5K Sep 27, 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XLRN Option to Purchase Common Stock Options Exercise $0 -5K -16.67% $0.00 25K Sep 27, 2021 Common Stock 5K $40.61 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2 The shares of common stock underlying this stock option award vested as to 25% of the shares on the first anniversary of February 12, 2018 and the remaining shares vest in equal quarterly installments over the following three years thereafter.